The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis
Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · 2026
DOI: 10.5543/tkda.2024.86907 ↗Kurz gefasst
Fallbericht in der Zeitschrift Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 2026. Verfasst von Mert Doğan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Bioprosthesis, Cardiac Resynchronization Therapy.
Abstract (Originalsprache)
The peri-procedural management of novel oral anticoagulants (NOAC) should be individualized based on patient-specific factors (age, body weight, renal function, concomitant medications, history of thromboembolic or bleeding events, and the presence of prosthetic valve) as well as procedural characteristics (bleeding risk). Less invasive procedures carry a relatively low bleeding risk and may be performed with minimal or no interruption of NOAC therapy. However, upgrading from an implantable cardioverter-defibrillator (ICD) to cardiac resynchronization therapy (CRT) is more complex than initial implantation. Therefore, the timing of the last NOAC dose before an elective procedure requires careful judgment, balancing individual risks and benefits. Herein, we present the case of an elderly patient with atrial fibrillation, grade IIIb chronic renal disease, low body weight, and a bioprosthetic mitral valve, who underwent an upgrade from an implantable cardioverter-defibrillator (ICD) to cardiac resynchronization therapy with a defibrillator (CRT-D). The patient developed bioprosthetic valve thrombosis 24 hours after edoxaban interruption without heparin bridging, which was successfully treated with ultraslow tissue plasminogen activator (tPA) therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
Zitieren
APA
Doğan, M., & Canpolat, U. (2026). The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. https://doi.org/10.5543/tkda.2024.86907
Vancouver
Doğan M, Canpolat U. The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. 2026. doi:10.5543/tkda.2024.86907
BibTeX
@article{Doan2026,
author = {Doğan, Mert and Canpolat, Uğur},
title = {The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis},
journal = {Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology},
year = {2026},
doi = {10.5543/tkda.2024.86907}
}
EUVIMED